Immunostimulatory plasmids
The present invention relates to immunomodulator compositions and methods of use as well as methods of making. The immunomodulator compositions comprise immunostimulatory plasmids, or DNA sequence, capable of eliciting an immune response in a recipient subject. Further, the immunostimulatory plasmids, or DNA sequence, do not contain antibiotic resistance coding sequence to help reduce the potential of horizontal transfer of antibiotic resistance in a population.
1. A method of stimulating an immune response in a subject comprising administering to the subject an immunostimulatory composition comprising:
a. a nucleic acid molecule having at least 84% sequence homology with the sequence of SEQ ID NO: 4 and at least 200 CpG dinucleotides; and
b. a cationic liposome delivery vehicle,
wherein an immune response is stimulated in the subject.
2. The method of claim 1 , wherein the liposome delivery vehicle comprises lipids selected from the group consisting of multilamellar vesicle lipids and extruded lipids.
3. The method of claim 1 , wherein the liposome delivery vehicle comprises pairs of lipids selected from the group consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and cholesterol; N[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) and cholesterol; 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM) and cholesterol; and dimethyldioctadecylammonium bromide (DDAB) and cholesterol.
4. The method of claim 1 , wherein administration is intravenously, intramuscularly, intradermally, intraperitoneally, subcutaneously, by spray, by aerosol, in ovo, orally, intraocularly, intratracheally, or intranasally.
5. The method of claim 1 , wherein the immunostimulatory composition further comprises a biological agent.
6. The method of claim 1 , wherein the biological agent is an immune enhancer protein, immunogen, vaccine, antimicrobial, or any combination thereof.
7. The method of claim 1 , wherein the administration is before exposure to an infectious agent.
8. The method of claim 1 , wherein the administration is after exposure to an infectious agent.
9. The method of claim 8 , wherein the immune response stimulated is selected from the group consisting of a non-antigen specific immune response, an antigen specific immune response, an innate immune response, an adaptive immune response, a humoral immune response, a cell-mediated immune response, or a combination thereof.
10. The method of claim 1 , wherein the subject is a mammalian species, aquaculture species, or avian species.
11. The method of claim 1 , wherein the nucleic acid molecule does not code for an immunogen.
12. The method of claim 11 , wherein the nucleic acid molecule has at least 90% sequence homology with the sequence of SEQ ID NO: 4.
13. The method of claim 11 , wherein the nucleic acid molecule comprises SEQ ID NO: 4.
14. The method of claim 11 , wherein the nucleic molecule has at least 260 CpG dinucleotides.
15. The method of claim 11 , wherein the nucleic acid molecule has at least 280 CpG dinucleotides.
16. The method of claim 11 , wherein the nucleic acid molecule has 283 CpG dinucleotides.
17. The method of claim 11 , wherein the nucleic acid molecule further comprises a selectable marker.
18. The method of claim 17 , wherein the selectable marker is LacZ.
19. The method of claim 1 , wherein the nucleic acid molecule has at least 91% sequence homology with the sequence of SEQ ID NO: 4.
20. The method of claim 11 , wherein the liposome delivery vehicle comprises pairs of lipids selected from the group consisting of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and cholesterol; N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTAP) and cholesterol; 1-[2-(oleoyloxy)ethyl]-2-oleyl-3-(2-hydroxyethyl)imidazolinium chloride (DOTIM) and cholesterol; and dimethyldioctadecylammonium bromide (DDAB) and cholesterol.